Neurocrine's movement disorder drug meets main goal in mid-stage study

(Reuters) - Neurocrine Biosciences Inc said its movement disorder drug showed a reduction in symptoms compared to a placebo in a mid-stage study, sending its shares up 56 percent after the bell.

via Reuters: Health News Read More Here..

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Lake forest health and fitness http://healthandfitness1blog.blogspot.com/2014/01/neurocrine-movement-disorder-drug-meets.html